Company research / TNGX
Tango Therapeutics, Inc. (TNGX)
- Sector Manufacturing
- Incorporated DE
- Fiscal year ends Dec 31
For the year ended 2025-12-31, Tango Therapeutics, Inc. reported revenue of $62.38M. Revenue grew 48.3% from the prior annual period.
Key ratios (year ended 2025-12-31)
-178.4%
Operating margin
-162.9%
Net margin
-29.3%
Return on year-end equity
48.3%
Revenue growth (YoY)
Beyond the statements
Follow the company.
Explore new filings, reported insider transactions and company relationships.